

Polyclonal Anti-*Mycobacterium leprae* MLSA-LAM (antiserum, Rabbit)

Catalog No. NR-19357

This reagent is the tangible property of the U.S. Government.

For research use only. Not for human use.

Contributor:

BEI Resources or NIH – Leprosy Research Support Contract

Manufacturer:

Karen Dobos, Ph.D., Colorado State University, Fort Collins, Colorado, USA and NIH – Leprosy Research Support Contract

Product Description:

Antibody Designation: anti-MLSA-LAM
 Polyclonal antiserum to soluble cytosolic antigen minus lipoarabinomannan (MLSA-LAM) of *Mycobacterium leprae* was produced in rabbits. The LAM was removed from the cytosolic protein fraction by TX-114 extraction. The antiserum is reported to be active in ELISA and Western Blot assays.

Material Provided:

Each vial contains approximately 250 µL of lyophilized NR-19357 provided as serum.

Note: NR-19357 can be reconstituted in sterile distilled water.

Packaging/Storage:

NR-19357 was packaged aseptically in cryovials. The product is provided frozen and should be stored at -80°C or colder immediately upon arrival. Freeze-thaw cycles should be avoided.

Citation:

Acknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Polyclonal Anti-*Mycobacterium leprae* MLSA-LAM (antiserum, Rabbit), NR-19357.”

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The

MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale. This material may be subject to third party patent rights.

References:

1. Cole, S. T., et al. “Massive Gene Decay in the Leprosy Bacillus.” Nature 409 (2001): 1007-1011. PubMed: 11234002.
2. Weir, R. E., et al. “Use of a Whole Blood Assay to Evaluate *in vitro* T Cell Responses to New Leprosy Skin Test Antigens in Leprosy Patients and Healthy Subjects.” Clin. Exp. Immunol. 116 (1999): 263-269. PubMed: 10337017.
3. Brennan, P. J. “Skin Test Development in Leprosy: Progress with First-Generation Skin Test Antigens, and an Approach to the Second Generation.” Lepr. Rev. 71 (2000) Suppl S50-4. PubMed: 11201887.
4. Spencer, J. S., et al. “Analysis of Antibody Responses to *Mycobacterium leprae* Phenolic Glycolipid I, Lipoarabinomannan, and Recombinant Proteins to Define Disease Subtype-Specific Antigenic Profiles in Leprosy.” Clin. Vaccine Immunol. 18 (2011): 260-267. PubMed: 21177913.

ATCC® is a trademark of the American Type Culture Collection.

